Miopatías inflamatorias idiopáticas: una mirada actualizada al diagnóstico y el manejo / Idiopathic inflammatory myopathies: a review
Rev. méd. Chile
;
147(3): 342-355, mar. 2019. tab, graf
Article
Dans Espagnol
| LILACS
| ID: biblio-1004355
ABSTRACT
Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of acquired immune-mediated diseases, which typically involve the striated muscle with a variable involvement of the skin and other organs. Clinically, they are characterized by proximal muscle weakness, elevation of muscle enzymes, myopathic changes on electromyography and an abnormal muscle biopsy. The different IIM have been classified according to their distinctive histopathologic features in dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM) and immune-mediated necrotizing myopathy (IMNM). Several myositis-specific antibodies are associated with the different phenotypes, as well as with different risk of neoplastic disease and systemic complications. The basis for the treatment of DM, PM, and IMNM is immunosuppression. For IBM there are only symptomatic treatments. Steroids, associated or not with other immunosuppressant drugs, are the first line of treatment. Biologic drugs will allow future individualized therapies. The 10-year survival of DM, PM and IMNM is 62 to 90%. The leading causes of death are neoplastic, lung and cardiac complications. IBM does not impair survival, although it affects the quality of life.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Myosite
Type d'étude:
Etude diagnostique
Limites du sujet:
Humains
langue:
Espagnol
Texte intégral:
Rev. méd. Chile
Thème du journal:
Médicament
Année:
2019
Type:
Article
Pays d'affiliation:
Chili
Institution/Pays d'affiliation:
Universidad del Desarrollo/CL
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS